Source: Eye Future; Editor: Seven KiteReprint requirements: Can be reprinted 24 hours after the first publication, source must be credited.
Recently, HSGD, a leading enterprise in the field of glaucoma innovative medical devices in China ——HSGD (Suzhou) Biomedical Technology Co., Ltd.("HSGD" for short)Completed a new round of financing, this round of financing was led byGuohai Innovative CapitalLeading investment,Suzhou Industrial Park Science and Technology Innovation FundFollow-up Investment.
This round of financing is mainly used to advance the companyHSGD Glaucoma IOP Monitoring Product® Large-scale production and commercialization,HSGD is gradually forming a patient-centered approach for glaucoma patients,Integration of preoperative screening, intraoperative treatment, and postoperative IOP managementA full-scenario solution provider integrated into one.
As of the date of this report, the company's financing history is as follows:
In addition,HSGD is committed toHigh-End Implantable Medical Devices for Blinding Ophthalmic DiseasesField,Developed minimally invasive glaucoma surgery (MIGS) instruments and delivery systemsSystem。As a leading enterprise in the field of China's new generation of MIGS, HSGD has built a complete product matrix, accelerating breakthroughs in related products for China's new generation of MIGS.
The product with the fastest advancement and already entered the innovation channel is"MicroCOGO Trabecular Micro-Stent Drainage System"，Since entering the National Medical Device Innovation "Green Channel" in February 2024, the product has been rolled out across China.Completed Over a Hundred Surgeries，Demonstrated excellent efficacy and safetySex，YesChinese Enterprises Entering the Clinical StageMinimum Class III Implants。The company is alsoThe First in ChinaAn innovative medical device company that has mass-produced the next-generation MIGS product and entered the clinical trial stage.Another product of the company"PassCOGO® Glaucoma Drainage System" has also entered the clinical trial stage.. This product belongs to the reconstruction of drainage pathways, achieving long-term stable control of intraocular pressure by establishing a new aqueous humor drainage pathway between the anterior chamber and the subconjunctival space. This also makes the companyOne of the companies with the most comprehensive product pipelines for MIGS procedures globally。
The treatment of glaucoma is mainly achieved through intraocular pressure intervention, and intraocular pressure monitoring is an indispensable part of disease management.
Innovatively developed by HSGDHSM®The rebound tonometer provides patients with a convenient method for daily intraocular pressure monitoring without the need to register or queue at the hospital.Handheld TonometerCan help patients achieve self-management of daily intraocular pressure monitoring., which can be carried around for measurement at any time, allowing doctors to promptly monitor patients' intraocular pressure fluctuation curves and carry out precise interventions in the course of the disease.
The product has recently obtained the national medical device registration license., will soon be launched in the market.
# Overview of the Tonometer MarketChina is a populous country with a large number of patients suffering from cataracts and glaucoma, among which currentlyThe number of glaucoma patients has reached approximately 21.5 million.. Against the backdrop of an aging population and increasing prevalence of electronic products, the number of glaucoma patients will continue to rise. Glaucoma is one of the three major blinding eye diseases, and due to the large population base,The Number of People Blinded by Glaucoma in China is Relatively High, Reaching Approximately 6 MillionCurrently, the early screening rate for glaucoma is relatively low in China.A Broad Space for Glaucoma Diagnosis Needs。Against the backdrop of an aging population, the demand for glaucoma diagnosis continues to grow.Boosting the Development of the Intraocular Pressure Monitor MarketAttracted by the broad market prospects, an increasing number of companies, including Finland's Icare, Switzerland's Sensimed, Implandata in Hannover, Germany, and Agile Medical, are expanding their global presence in the field of intraocular pressure monitors. Application scenarios include ophthalmic hospitals, eyewear stores, etc. With the growing demand for real-time monitoring,The application scenarios of intraocular pressure monitors are continuously expanding into the home domain.。According toMordor Intelligence data,EyePressure Gauge Market SizeIt was $356.56 million in 2024 and is expected to reach $456.16 million by 2029., with a compound annual growth rate (CAGR) of 5.05% during the forecast period (2024-2029).
▲Originated fromMordor Intelligence
The tonometer market was impacted by the outbreak of COVID-19, primarily due to lockdowns implemented in multiple countries, significantly reducing visits to ophthalmic centers or hospitals, where only emergency surgeries were performed. This decreased the sales volume of tonometer devices and affected the corporate revenue of market participants. However,With all restrictions gradually lifted and the resumption of ophthalmic services, the market is expected to grow during the research period.。The high burden of glaucoma has increased the demand for tonometers, which is expected to drive market growth during the research period. For example, according to a report released by the World Health Organization in October 2022, 7.7 million people worldwide have moderate or severe distance vision impairment or blindness due to glaucoma. Additionally, according to the same source, glaucoma is more prevalent in high-income countries. Therefore, due toThe high burden of glaucoma has increased the demand for tonometers to measure intraocular pressure, and the market is expected to grow significantly during the study period.。In addition, the approval and launch of new products have increased the widespread distribution of tonometer devices across various regions. For example, in November 2022, the U.S. Department of Veterans Affairs (VA) and the Lovell Federal Health Care Center provided the CATS disposable tonometer prism (CATS-D). Consequently,The new approval for market participants expands their product portfolios, and the market is expected to witness significant growth during the forecast period.。Currently inIn China,There are few convenient, fast, and home self-test rebound tonometers, indicating a huge market gap.。As of July 23, 2024,IChinaOnly Four Rebound Tonometers Have Been Approved for Marketing by the National Medical Products Administration in China(Two domestically produced, two imported), the manufacturers are respectivelyMicroWisdom Medical Devices Co., Ltd.、Tianjin Suowei Electronic Technology Co., Ltd.,Finland Aikai Co., Ltd.，There is a large space for domestically produced alternatives.
▲ Originated fromNational Medical Products Administration
HSGD (Suzhou) Biomedical Technology Co., Ltd. (referred to as "HSGD") was established in September 2020, with its headquarters located in Suzhou Industrial Park Biobay. It is a company focused onInnovative Minimally Invasive Solutions in the Field of GlaucomaAn innovative technology enterprise developing a full pipeline of products. HSGD's newly developed generation of MIGS products significantly broadens the surgical applicable population due to their excellent safety and efficacy.MicroCOGO® Trabecular Micro-Stent Drainage SystemFor patients with early to mid-stage open-angle glaucoma, is currentlyChinese companies entering the clinical stageMinimum Class III Implants. According to the company's person in charge, this systemThe diameter of the peripheral stent is less than 300 micrometers., The stent also features highly precise drainage channels, special coatings, and other designs, with the smallest drainage pore size being approximately forty to fifty micrometers.▲Image source: Company official websiteThe working principle of MicroCOGO® isImplanting stents into the trabecular meshwork through an extremely fine needle, with its head embedded in Schlemm's canal and its tail exposed to the anterior chamber. The hollow lumen and side holes of the trabecular micro-stent create an aqueous humor channel across the trabecular meshwork, bypassing the obstructed trabecular meshwork to promote aqueous outflow, thereby reducing intraocular pressure in glaucoma patients.▲Image source: Company official websiteAs of the date of publication, the following partial patent information of the company has been queried:
